啟明醫療-B(02500.HK)擬根據一般授權配售1804.25萬股 總籌約14.45億港元
格隆匯 1 月 22日丨啟明醫療-B(02500.HK)發佈公吿,2021年1月22日(交易時段前),公司與配售代理(即高盛及UBS)訂立配售協議,內容有關按配售價每股配售股份80.08港元向不少於六名並非公司關連人士的專業、機構及╱或個人投資者配售合共1804.25萬股新H股。
配售股份分別佔配售前公司已發行H股總數及已發行股份總數約4.36%及4.27%,並分別佔經配發及發行配售股份擴大後的公司已發行H股總數及已發行股份總數約4.18%及4.09%。配售價每股配售股份80.08港元較2021年1月21日在香港聯交所所報收市價每股H股82.20港元折讓約2.6%。
假設所有配售股份獲悉數配售,配售所得款項總額預計約為14.45億港元及配售所得款項淨額預計約為14.27億港元。公司擬將配售所得款項淨額用於加速公司在研產品的開發及研究,其中包括Venus PowerX Valve、Venus Vitae Valve、臨牀前階段主動瓣膜修復裝置(Leaflex)、經導管二尖瓣置換術(TMVR)、經導管三尖瓣置換術(TTVR)等產品及技術;其他新技術的開發和投資;及作運營資金及其他一般企業用途。配售股份將根據一般性授權予以配發及發行。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.